| Name | Title | Contact Details |
|---|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
Oryzon’s MISSION is to identify and manipulate biomarkers -genes and proteins- allowing the development of new therapeutic tools in the quest to improve human health – covering unmet clinical needs- and in benefits for our shareholders. Oryzon’s VISION is to become a world leader company in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
NaturalCheck is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
fusionmed is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our proprietary and vertically integrated technology solutions empower clients to improve patient outcomes and enhance medication adherence through improved access (virtual care and MTM), owned pharmacy infrastructure and physician network, information...